Press release
Primary Sclerosing Cholangitis Market Overview 2020 By In-Depth Analysis, Growth Opportunities, CAGR Status, Sales Volume and Forecast To 2028 | NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc
Primary Sclerosing Cholangitis Market
The primary sclerosing cholangitis market is estimated to grow at high CAGR over the forecast period.This research report offers broad analysis of development drivers, market landscape, recent progressions, as well as business patterns. The market report also covers conventional services and market strategies in order to better understand the global market scenario. The research report investigates the number of distinctive prospects in the target market for numerous financial partners & specialists. This research report is a follow-up of wide-ranging global distribution network as well as manufacturing and flexible product abilities. Moreover, the report studies the market position and the potential of regional and global providers with respect to end industries/ applications &product regions.
Get Sample Copy of This Report @ https://www.quincemarketinsights.com/request-sample-67711?utm_source=OpenPR&utm_medium=SA
Market Scope:
The global primary sclerosing cholangitis market report offers in-depth data about the opportunities, major drivers, and market restraints of the global market and its influence analysis lengthily. Also, the report also provides a complete study of technological advances in the global market such as agreements, acquisitions, collaborations, product launches, and mergers to know the market dynamics for future growth. This study is helpful for the consumers who are interested to invest in global market.
Increase in occurrence of liver diseases and rise in alcohol consumption are expected to drive the global primary sclerosing cholangitis market over the mentioned timeframe. According to the Centers for Disease Control and Prevention, the rising incidence of liver disease across the globe was 3.9 million in 2016. As per the WHO (World Health Organization), occurrence of liver cirrhosis is increasing in the countries in Europe owing to high consumption of alcohol. Additionally, increase in awareness programs and rise in R&D increasing investment for growth of new drug molecules are expected to propel the global primary sclerosing cholangitis market in the near future. On the other hand, high cost of drug growth and stringent government regulations are anticipated to restrain the primary sclerosing cholangitis treatment market over the prediction period.
Segment Analysis of Global Primary Sclerosing Cholangitis Market
Global primary sclerosing market is segmented into type, symptom control, treatment type, end user, and geographical regions.
• In terms of type, this market is segmented into classic PSC, small-duct PSC, and PSC associated with autoimmune hepatitis.
• On the basis of treatment type, the global market is segregated into methotrexate, ursodexycholic acid, corticosteroids, obeticholic acid, and others.
• In terms of symptom control, the market segregated into antibacterials, antithistamines, colestipol, cholestyramine, opioid antagonists, and others.
• Based on end-user, the market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies.
Get ToC for the overview of the premium report : https://www.quincemarketinsights.com/request-toc-67711?utm_source=OpenPR&utm_medium=SA
Geographical Analysis of Global Primary Sclerosing Cholangitis Market
Geographically, the global primary sclerosing cholangitis treatment market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Out of these, North America is likely to account for the leading share of the global primary sclerosing cholangitis treatment market owing to favorable reimbursement scenario and greater health care spending.
Recent Strategic Developments of Major Global Primary Sclerosing Cholangitis Market
• In 2016, there were 227,400 prevalent cases of PSC (primary sclerosing cholangitis) globally among adults aged 30 years and over, and predictions that number to raise to 265,700 prevalent cases by 2025.
• Most of the industry-sponsored drugs in active clinical 2q expansion for PSC are in Phase II, with only one drug in Phase III. Therapies in the pipeline for PSC focus on a huge variety of targets.
Competitive Landscape of Global Primary Sclerosing Cholangitis Market
Key players operating in the global primary sclerosing cholangitis treatment market are Pfizer, Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., Glenmark Pharmaceuticals, Novartis AG, Merck & Co., Inc.,Takeda Pharmaceuticals Company Ltd., and Zydus Pharmaceuticals Inc., among others.
Make An Inquiry For Purchasing This Report @ https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-67711?utm_source=OpenPR&utm_medium=SA
Market Segmentation:
By Drug:
• BT1023
• GS-9674
• NGM282
• OCA
• LUM001
• Others
By Region:
North America Primary Sclerosing Cholangitis Market
• North America, by Country
o US
o Canada
o Mexico
• North America, by Drug
Europe Primary Sclerosing Cholangitis Market
• Europe, by Country
o Germany
o Russia
o UK
o France
o Italy
o Spain
o The Netherlands
o Rest of Europe
• Europe, by Drug
Asia Pacific Primary Sclerosing Cholangitis Market
• Asia Pacific, by Country
o China
o India
o Japan
o South Korea
o Australia
o Indonesia
o Rest of Asia Pacific
• Asia Pacific, by Drug
Middle East & Africa Primary Sclerosing Cholangitis Market
• Middle East & Africa, by Country
o UAE
o Saudi Arabia
o Qatar
o South Africa
o Rest of Middle East & Africa
• Middle East & Africa, by Drug
South America Primary Sclerosing Cholangitis Market
• South America, by Country
o Brazil
o Argentina
o Colombia
o Rest of South America
• South America, by Drug
Contact:
Quince Market Insights
Ajay D. (Knowledge Partner)
Office No- A109
Pune, Maharashtra 411028
Phone: +91 706 672 4848 +1 208 405 2835 /+44 1444 39 0986
Email: sales@quincemarketinsights.com
Web: www.quincemarketinsights.com
ABOUT US:
QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the world's most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Sclerosing Cholangitis Market Overview 2020 By In-Depth Analysis, Growth Opportunities, CAGR Status, Sales Volume and Forecast To 2028 | NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc here
News-ID: 2108627 • Views: …
More Releases from QUINCE MARKET INISGHTS
Vertical Farming Market to Register a CAGR of 23.98% During Forecast Period| Key …
The Vertical Farming Market size is predicted to reach USD 8.92 Billion exhibiting a CAGR of 23.98% during forecast period.
Stacking farms vertically is referred to as vertical agriculture. Because of this, small land may now be used for greater productivity. It is an atypical technique for growing crops that allows for simple harvesting, insignificant climatic effects, great yields, less pesticide use, smaller crop requirements, and reduced water use.
Click here…
Sympathomimetic Drug Market is Predicted to Grow at a CAGR of 11.34% During Fore …
The Global Sympathomimetic Drug Market reach USD 9.87 Billion in 2021 and is expected to exhibit a CAGR of 11.34% over the forecast period 2023 to 2032.
To boost the sympathetic nervous system's endogenous catecholamines for therapeutic purposes, sympathomimetic medications are employed. These medications mimic or promote the function of the chemical messenger's epinephrine and norepinephrine from the adrenal gland.
Click Here to Get a Free Sample Report of this Market-…
Clean Label Ingredients Market to Register a CAGR of 7.1% over the Forecast Peri …
The global clean label ingredients market was estimated at USD 39.21 billion in 2018 and it is anticipated to exhibit a CAGR of 7.1% over the forecast period.
Clean label, in the eyes of consumers, refers to ingredients that are easy to understand and identify, are raw and minimally processed, and do not contain any additives or preservatives. Although the exact concept is debatable, the defining problem for our industry is…
Advanced Driver Assistance System (ADAS) Market Top Manufacturers, Future Growth …
The report also studies the recent industry market dynamics like opportunities, challenges, driving factors, restraining factors as well as market news like investments, mergers and acquisitions. It also offers market size, growth rate by types, application as well as compile quantitative and qualitative methods for making micro and macroeconomic forecasts in various countries and regions.
This market research report helps in understanding the market and market strategies for the expansions for…
More Releases for Primary
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
